Key result
Thrombotest was found to have no major advantage over thromboplastin for the laboratory control of anticoagulant therapy.
Why the study?
Does Thrombotest provide an advantage over thromboplastin for the laboratory control of anticoagulant therapy?
Observational
Does Thrombotest provide an advantage over thromboplastin for the laboratory control of anticoagulant therapy?
Answers are grounded in this paper and cite their sources.
Thrombotest offers no major advantage over standard thromboplastin levels for monitoring patients on anticoagulant therapy.
An investigation into the laboratory control of anticoagulant therapy is presented. The cases were divided into those in the first few weeks of therapy and those on long-term treatment. Variations in the levels of factors VII and X, and factor IX were assessed. Thromboplastin levels were used to control therapy. These were compared with parallel estimations by Thrombotest and with the levels of the coagulation factors. Thrombotest was found to have no major advantage over thromboplastin.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (1965) conducted an observational in Anticoagulant therapy. Thrombotest vs. Thromboplastin was evaluated on Laboratory control of anticoagulant therapy. Thrombotest was found to have no major advantage over thromboplastin for the laboratory control of anticoagulant therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: